Timothy Stanley Maughan

Professor of Clinical Oncology, CRUK/MRC Oxford Institute for Radiation Oncology

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Timothy Stanley Maughan is a Professor of Clinical Oncology at the CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, UK. His research primarily focuses on colorectal cancer, particularly the coevolution of mutations, imaging modalities, and personalized treatment strategies. He has published extensively on topics including the efficacy of novel therapies in BRAF-mutant colorectal cancer and innovative radiotherapy techniques for pancreatic cancer.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (33)

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM

Timothy Stanley Maughan

Research Interests

Explore related searches

Contact this professor

About

Articles (29)

Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Tumour purity assessment with deep learning in colorectal cancer and impact on molecular analysis

Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

Relationship between inherited genetic variation and survival from colorectal cancer stratified by tumour location.

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer

New role of fat-free mass in cancer risk linked with genetic predisposition.

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial

Adaptive MR-Guided Stereotactic Ablative Body Radiotherapy (MRgSABR) for Pancreas Cancer: Dosimetric Evaluation from EMERALD Trial

TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival.

515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)

Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.

Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK

Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.

Modeling Acute Chemoradiotherapy (CRT) Diarrhea Severity Using Automatically Contoured Small Bowel

Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer

Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer

A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.

Modelling of Dosimetric Impact of Visceral Organ Variability During MRI-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas.

BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.

Collaborators (33)

Patricia Roxburgh

Maxime Lafarge

Thierry André

Zhuoyan Shen

Emma M. Kerr

Matthew Parkes

Tatsuya Suwa

Nicholas West

Ignacio Soriano

Jane Holmes

David J. Fisher

Pradeep Virdee

Philip Dunne

Ultan McDermott

Lisette Nixon

Richard Adams

Ping Zhang

Louise Brown

Emiliano Spezi

Richard Wilson

Leslie Samuel

Alexander Ooms

Cathy Eng

Hannah Deborah West

Chris Hurt

Joanne Edwards

Simon McDade

Marc Buyse

Eric Van Cutsem

David Sebag-Montefiore

David Kerr

Marco Viviani

Tom Whyntie

Make your next move.